Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Sleep Disorder

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    320 result(s) found for: Sleep Disorder. Displaying page 5 of 16.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2020-001176-15 Sponsor Protocol Number: BIA-91067-405 Start Date*: 2021-05-07
    Sponsor Name:Bial - Portela & Ca, S.A.
    Full Title: Open-label, single-arm, pilot study to evaluate the effect of opicapone 50 mg on Parkinson’s disease patients with end-of-dose motor fluctuations and associated sleep disorders.
    Medical condition: Parkinson's disease patients with wearing-off motor fluctuations and associated sleep disorders.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) PT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-002088-18 Sponsor Protocol Number: H3A106104 Start Date*: 2006-10-12
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: An open label, dose escalation study with a double blind randomised placebo controlled withdrawal to examine the effects of the histamine H3 antagonist GSK189254 in patients with narcolepsy.
    Medical condition: Narcolepsy
    Disease: Version SOC Term Classification Code Term Level
    8.1 10028713 Narcolepsy LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) GB (Prematurely Ended) NL (Prematurely Ended) AT (Completed) FI (Prematurely Ended) ES (Completed)
    Trial results: View results
    EudraCT Number: 2011-003486-15 Sponsor Protocol Number: SP0934 Start Date*: 2012-06-13
    Sponsor Name:UCB BIOSCIENCES GmbH
    Full Title: A multi-center, randomized, double-blind, placebo-controlled, parallel group, polysomnography study to investigate safety and efficacy of the rotigotine transdermal patch in subjects with Restless ...
    Medical condition: Restless Legs Syndrome in patients with End Stage Renal Disease (ESRD)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10029205 Nervous system disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FI (Completed) AT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-004644-38 Sponsor Protocol Number: ID-078A303 Start Date*: 2018-10-30
    Sponsor Name:Idorsia Pharmaceuticals Ltd
    Full Title: Multi-center, double-blind, parallel-group, randomized, placebo-controlled, three doses, 40-week extension to studies ID-078A301 and ID-078A302 to assess the long term safety and tolerability of AC...
    Medical condition: Insomnia disorder
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10022437 Insomnia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) FI (Completed) SE (Completed) DE (Completed) CZ (Completed) FR (Completed) HU (Completed) ES (Completed) BG (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-000359-29 Sponsor Protocol Number: CLFT218-1501 Start Date*: 2016-11-09
    Sponsor Name:Flamel Ireland Limited (trading under the business name Avadel Ireland)
    Full Title: A Double-blind, Randomized, Placebo Controlled, Two Arm Multi-center Study to Assess the Efficacy and Safety of a Once Nightly Formulation of Sodium Oxybate for Extended-Release Oral Suspension (FT...
    Medical condition: The treatment of cataplexy and excessive daytime sleepiness on narcolepsy.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10007738 Cataplexy and narcolepsy LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DK (Prematurely Ended) DE (Completed) GB (Completed) FI (Completed) CZ (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2010-019464-37 Sponsor Protocol Number: 2010-019464-37 Start Date*: 2011-04-14
    Sponsor Name:FONDAZIONE TOSCANA GABRIELE MONASTERIO
    Full Title: effects of dynamic co2 therapy in periodic breathing in heart failure patients
    Medical condition: Patients hospitalized for heart failure and central sleep apnea syndrome in the Cardiovascular Medicine Department, Fondazione G. Monasterio, Pisa
    Disease: Version SOC Term Classification Code Term Level
    14.1 10007541 - Cardiac disorders 10007541 Cardiac disorders SOC
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-016713-20 Sponsor Protocol Number: CL2-20098-072 Start Date*: 2010-04-13
    Sponsor Name:Laboratorios Servier S.L.
    Full Title: Eficacia de agomelatina 25mg/día (con posibilidad de incremento a 50mg/día tras 8 semanas de tratamiento) por vía oral durante 16 semanas en pacientes con Trastorno Obsesivo Compulsivo // Efficacy...
    Medical condition: Trastorno Obsesivo Compulsivo // Obsessive-compulsive disorder
    Disease: Version SOC Term Classification Code Term Level
    12.1 10029898 Obsessive-compulsive disorder LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed) SE (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-013789-17 Sponsor Protocol Number: CL3-20098-071 Start Date*: 2010-03-11
    Sponsor Name:Institut de Recherches Internationales Servier
    Full Title: Efficacy and safety of agomelatine (25 mg/day with potential blinded adjustment to 50 mg/day) for 12 weeks in non-depressed out-patients with Generalized Anxiety Disorder. A 12-week randomised, dou...
    Medical condition: Generalized anxiety disorder
    Disease: Version SOC Term Classification Code Term Level
    13.1 10037175 - Psychiatric disorders 10018105 Generalized anxiety disorder LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed) CZ (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2014-005111-16 Sponsor Protocol Number: XP-IIT-0029 Start Date*: 2015-02-16
    Sponsor Name:Instituto de Investigaciones del Sueño
    Full Title: Response to gabapentin enacarbil in two groups of RLS patients: Previously exposed to long-term treatment with dopaminergic agents versus dopaminergic treatment-naive patients.
    Medical condition: RLS
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2012-003699-37 Sponsor Protocol Number: CL3-20098-089 Start Date*: 2013-01-17
    Sponsor Name:Institut de Recherches Internationales Servier
    Full Title: Efficacy and safety of agomelatine (25mg/day with blinded potential adjustment to 50mg/day) versus escitalopram (10mg/day with blinded potential adjustment to 20mg/day) given orally for 12 weeks in...
    Medical condition: Generalized Anxiety Disorder
    Disease: Version SOC Term Classification Code Term Level
    14.1 10037175 - Psychiatric disorders 10018075 Generalised anxiety disorder PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Completed) HU (Completed) PL (Completed) FI (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2015-000488-15 Sponsor Protocol Number: 3.0 Start Date*: 2015-10-07
    Sponsor Name:University of Leipzig
    Full Title: Vigilance regulation as predictor of response to Psychostimulants in adult patients with ADHD
    Medical condition: Attention deficit-hyperactivity disorder
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004873 10003735 Attention deficit-hyperactivity disorder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-002196-35 Sponsor Protocol Number: 73520 Start Date*: 2020-11-16
    Sponsor Name:Amsterdam UMC, location VUmc
    Full Title: post-trial access cohort BUmetanide for Developmental DIsorders
    Medical condition: Neurodevelopmental disorders Autism spectrum disorder Attention deficit hyperactivity disorder (ADHD) Learning disorders
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-004884-30 Sponsor Protocol Number: P13-04/BP1.4979 Start Date*: 2017-12-07
    Sponsor Name:BIOPROJET PHARMA
    Full Title: Randomized double blind parallel groups sequential, placebo controlled, trial assessing the efficacy and safety of BP1.4979 in Resteless Legs Syndrome (RLS).
    Medical condition: Restless Legs Syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029205 - Nervous system disorders 10058920 Restless legs syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2004-004009-10 Sponsor Protocol Number: CL3-20098-046 Start Date*: 2005-06-29
    Sponsor Name:Institut de Recherches Internationales Servier [...]
    1. Institut de Recherches Internationales Servier
    2. Laboratorios Servier S.L. (For Spain only)
    Full Title: Efficacy of agomelatine (25 mg/day with potential adjustment to 50 mg) given orally on rest/activity circadian rhythms in outpatients with Major Depressive Disorder. A randomized, double-blind inte...
    Medical condition: Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    3.3 10025453 P.T.
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2014-005484-32 Sponsor Protocol Number: VN-FT-01 Start Date*: 2015-05-28
    Sponsor Name:Lund University
    Full Title: Double-blind, randomized placebo controlled study on the effect from cortisone treatment of vestibular neuritis - function, subjective well-being and stress
    Medical condition: Acute vestibular syndrome better known as Vestibular neuritis
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004863 10047392 Vestibular nerve damage LLT
    17.1 100000004854 10047388 Vestibular function disorder LLT
    17.1 100000004862 10051781 Vestibular paralysis LLT
    17.1 100000004854 10013285 Disorder vestibular LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-000862-14 Sponsor Protocol Number: A-bipolar Start Date*: 2021-07-08
    Sponsor Name:Copenhagen Affective Disorder research Center (CADIC),
    Full Title: Effects of low dose Aspirin in bipolar disorder – a randomized controlled trial (the A-Bipolar RCT)
    Medical condition: Bipolar disorder
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004873 10004935 Bipolar affective disorder, unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-003955-23 Sponsor Protocol Number: DR2 Start Date*: 2016-04-15
    Sponsor Name:Dept. of Ophthalmology, Rigshospitalet – Glostrup
    Full Title: Diabetic retinopathy: Effects of melatonin treatment on visual functions and circadian rhythm.
    Medical condition: Diabetic Retinopathy and Sleep disorder
    Disease: Version SOC Term Classification Code Term Level
    20.1 10015919 - Eye disorders 10012689 Diabetic retinopathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2005-002388-95 Sponsor Protocol Number: CL3-20098-048 Start Date*: 2005-11-02
    Sponsor Name:Institut de Recherches Internationales Servier [...]
    1. Institut de Recherches Internationales Servier
    2. Laboratorios Servier S.L. (For Spain only)
    Full Title: Efficacy of agomelatine (25 to 50 mg/day) given orally on quality of remission in elderly depressed patients, after a 12-week treatment period.A randomised, double-blind, flexible-dose internationa...
    Medical condition: Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    3.3 10025453 P.T.
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DK (Completed) ES (Completed) BE (Completed) PT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-015565-31 Sponsor Protocol Number: 4305-009 Start Date*: 2009-12-03
    Sponsor Name:Merck Sharp & Dohme (Sweden) AB
    Full Title: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Long Term Safety Study of MK-4305 in Patients with Primary Insomnia
    Medical condition: Primary Insomnia
    Disease: Version SOC Term Classification Code Term Level
    12.0 10036701 Primary insomnia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) ES (Completed) DE (Completed) BE (Completed) FI (Completed) DK (Completed) HU (Completed) FR (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-005573-51 Sponsor Protocol Number: CQVA149ANO01 Start Date*: 2014-08-28
    Sponsor Name:Novartis Sverige AB
    Full Title: A 12-week, multicenter, cross-over, placebo-controlled, double-blind study to determine the impact of QVA149 (indacaterol/glycopyrronium) 85/43 µg on nocturnal oxygen levels in Chronic Obstructive ...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) SE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Jun 12 13:23:34 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA